{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,15]],"date-time":"2024-09-15T00:08:28Z","timestamp":1726358908746},"reference-count":22,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,12,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Enthusiasm about interferons for the treatment of myeloproliferative neoplasms has recently arisen. How does a nontargeted therapy selectively target the malignant clone? Many foundational questions about interferon treatment are unanswered, including who, when, and for how long do we treat. Using an individual case, this review touches on gaps in risk assessment in polycythemia vera (PV) and essential thrombocythemia (ET) and the history of treatment with interferons. How is it that this proinflammatory cytokine effectively treats ET and PV, themselves proinflammatory states? We summarize existing mechanistic and clinical data, the molecular context as a modifier for treatment response, the establishment of treatment goals, and the challenges that lie ahead.<\/jats:p>","DOI":"10.1182\/hematology.2021000280","type":"journal-article","created":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T12:15:56Z","timestamp":1639138556000},"page":"463-468","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Running interferon interference in treating PV\/ET: meeting unmet needs"],"prefix":"10.1182","volume":"2021","author":[{"given":"Elizabeth A.","family":"Traxler","sequence":"first","affiliation":[{"name":"Department of Medicine and Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth O.","family":"Hexner","sequence":"additional","affiliation":[{"name":"Department of Medicine and Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2021,12,10]]},"reference":[{"issue":"October","key":"2021121012080009200_hem2021000280C1","doi-asserted-by":"crossref","first-page":"648090","DOI":"10.1155\/2015\/648090","article-title":"The role of reactive oxygen species in myelofibrosis and related neoplasms","volume":"2015","author":"Bj\u00f8rn","year":"2015","journal-title":"Mediators Inflamm"},{"issue":"11","key":"2021121012080009200_hem2021000280C2","doi-asserted-by":"crossref","first-page":"e112786","DOI":"10.1371\/journal.pone.0112786","article-title":"Whole blood transcriptional profiling reveals deregulation of oxidative and antioxidative defence genes in myelofibrosis and related neoplasms. Potential implications of downregulation of Nrf2 for genomic instability and disease progression","volume":"9","author":"Hasselbalch","year":"2014","journal-title":"PLoS ONE"},{"issue":"17","key":"2021121012080009200_hem2021000280C3","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1056\/NEJM198604243141701","article-title":"Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia","volume":"314","author":"Talpaz","year":"1986","journal-title":"N Engl J Med"},{"issue":"8607","key":"2021121012080009200_hem2021000280C4","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0140-6736(88)92881-4","article-title":"Recombinant interferon-alpha for treatment of polycythaemia vera","volume":"2","author":"Silver","year":"1988","journal-title":"Lancet"},{"issue":"1","key":"2021121012080009200_hem2021000280C5","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/BF00320230","article-title":"Treatment of thrombocytosis in myeloproliferative disorders with interferon alpha-2a","volume":"58","author":"Tichelli","year":"1989","journal-title":"Blut"},{"issue":"3","key":"2021121012080009200_hem2021000280C6","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.clim.2006.10.006","article-title":"Novel tumor antigens elicit anti-tumor humoral immune reactions in a subset of patients with polycythemia vera","volume":"122","author":"Xiong","year":"2007","journal-title":"Clin Immunol"},{"issue":"18","key":"2021121012080009200_hem2021000280C7","doi-asserted-by":"crossref","first-page":"4706","DOI":"10.1182\/blood-2010-08-258772","article-title":"The renaissance of interferon therapy for the treatment of myeloid malignancies","volume":"117","author":"Kiladjian","year":"2011","journal-title":"Blood"},{"issue":"8","key":"2021121012080009200_hem2021000280C8","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1056\/NEJM198102193040801","article-title":"Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy","volume":"304","author":"Berk","year":"1981","journal-title":"N Engl J Med"},{"issue":"1","key":"2021121012080009200_hem2021000280C9","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1208500","article-title":"Cardiovascular events and intensity of treatment in polycythemia vera","volume":"368","author":"Marchioli","year":"2013","journal-title":"N Engl J Med"},{"issue":"10","key":"2021121012080009200_hem2021000280C10","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.6004\/jnccn.2017.0157","article-title":"NCCN guidelines insights: myeloproliferative neoplasms, Version 2.2018","volume":"15","author":"Mesa","year":"2017","journal-title":"J Natl Compr Canc Netw"},{"issue":"6","key":"2021121012080009200_hem2021000280C11","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1182\/blood-2006-03-009860","article-title":"High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a","volume":"108","author":"Kiladjian","year":"2006","journal-title":"Blood"},{"issue":"4","key":"2021121012080009200_hem2021000280C12","doi-asserted-by":"crossref","first-page":"e150","DOI":"10.1016\/S2352-3026(17)30039-X","article-title":"Long-term treatment with interferon alfa for myeloproliferative neoplasms","volume":"4","author":"Kiladjian","year":"2017","journal-title":"Lancet Haematol"},{"issue":"32","key":"2021121012080009200_hem2021000280C13","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1200\/JCO.2009.23.6075","article-title":"Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera","volume":"27","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"J Clin Oncol"},{"issue":"12","key":"2021121012080009200_hem2021000280C14","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1038\/s41375-019-0524-7","article-title":"A prospective evaluation of pegy- lated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis","volume":"33","author":"Mascarenhas","year":"2019","journal-title":"Leukemia"},{"issue":"8","key":"2021121012080009200_hem2021000280C15","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1182\/blood-2008-03-143537","article-title":"Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera","volume":"112","author":"Kiladjian","year":"2008","journal-title":"Blood"},{"issue":"6","key":"2021121012080009200_hem2021000280C16","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1182\/blood-2012-07-442012","article-title":"Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon \u03b1-2a","volume":"122","author":"Quint\u00e1s-Cardama","year":"2013","journal-title":"Blood"},{"issue":"4","key":"2021121012080009200_hem2021000280C17","doi-asserted-by":"crossref","first-page":"e165","DOI":"10.1016\/S2352-3026(17)30030-3","article-title":"Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial","volume":"4","author":"Masarova","year":"2017","journal-title":"Lancet Haematol"},{"issue":"10","key":"2021121012080009200_hem2021000280C18","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1200\/JCO.2005.07.062","article-title":"Vascular and neoplastic risk in a large cohort of patients with polycythemia vera","volume":"23","author":"Marchioli","year":"2005","journal-title":"J Clin Oncol"},{"issue":"11","key":"2021121012080009200_hem2021000280C19","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41408-018-0151-y","article-title":"Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district: pooled analysis of 1500 cases","volume":"8","author":"De Stefano","year":"2018","journal-title":"Blood Cancer J"},{"issue":"3","key":"2021121012080009200_hem2021000280C20","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1016\/S2352-3026(19)30236-4","article-title":"Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study","volume":"7","author":"Gisslinger","year":"2020","journal-title":"Lancet Haematol"},{"journal-title":"Blood","article-title":"Inferring the dynamic of mutated hematopoietic stem and progenitor cells induced by IFN\u03b1 in myeloproliferative neoplasms","author":"Mosca","key":"2021121012080009200_hem2021000280C21"},{"issue":"5","key":"2021121012080009200_hem2021000280C22","doi-asserted-by":"crossref","first-page":"E114","DOI":"10.1002\/ajh.25748","article-title":"Pregnancy outcomes in myeloproliferative neoplasms: a Mayo Clinic report on 102 pregnancies","volume":"95","author":"Gangat","year":"2020","journal-title":"Am J Hematol"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2021\/1\/463\/1852047\/463traxler.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2021\/1\/463\/1852047\/463traxler.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,14]],"date-time":"2024-09-14T05:45:17Z","timestamp":1726292717000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2021\/1\/463\/482994\/Running-interferon-interference-in-treating-PV-ET"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,10]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12,10]]},"published-print":{"date-parts":[[2021,12,10]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2021000280","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"type":"print","value":"1520-4391"},{"type":"electronic","value":"1520-4383"}],"subject":[],"published-other":{"date-parts":[[2021,12,10]]},"published":{"date-parts":[[2021,12,10]]}}}